| | Advisory Board "We will surely get to our destination if we join hands."
- Aung San Suu Kyi, Burmese political leader
DSEC is driven by an esteemed Advisory Board of industry executives who believe that idea sharing and discussion among safety leaders of different companies can make a positive impact in how the industry develops safer and more effective medicines for patients. Each board member is an active participant in DSEC agenda planning as well as serving in an executive position at a prominent biopharmaceutical company.
Jack A. Reynolds, DVM, DACVP, DACLAM & FIATP
Chairman of the Advisory Board
Drug Safety Executive Council
Herman Van Cauteren
Senior Vice President / Global Head, GPCD
Johnson & Johnson PRD
Jerry Fisher
Senior Vice President, Office of the President
Wyeth
Jim Green
Senior Vice President, Preclinical and Clinical Development Sciences
Biogen Idec
Eckhard von Keutz
Senior Vice President, Global Head of Toxicology
Bayer HealthCare AG
Marc Bonnefoi
Global Head of Drug Safety Evaluation & Scientific Site Director for Sciences and Medical Affairs
sanofi-aventis
Ruth Lightfoot
Vice President, Comparative Biology & Safety Sciences
Amgen
Gregg Lundeen
Vice President, Toxicology
Eli Lilly
Peter Moldeus
Global Vice President, Drug Safety Evaluation
AstraZeneca
Thomas Singer
Global Head, Non Clinical Safety
F. Hoffmann-La Roche
Paul Trennery
Senior Vice President, Safety Assessments
GlaxoSmithKline
James Macdonald
Executive Vice President, Preclinical Development
Schering-Plough |